Olanzapine and amisulpride – practical benefits of their use in treatment Review article
Article Sidebar
Main Article Content
Abstract
The article presents olanzapine and amisulpride as two substances that have been successfully used in psychiatric practice for many years.
The mechanism of action of olanzapine in the CNS is described first. Then, an analysis of the broad clinical applications of this drug in a wide range of therapeutic doses is presented. After discussing the indications, contraindications and possible adverse effects, the focus is on the oral and intramuscular forms of olanzapine, and then the orally disintegrating tablet form is discussed in more detail. Practical conclusions presented the profile of patients in whom it is worth considering the use of olanzapine in the course of treatment of various mental disorders.
The second part of the study is devoted to amisulpride. The description of the mechanism of action, indications and contraindications is extended to include a discussion of the procedure for drug-induced hyperprolactinemia. Then, potential clinical situations in which patients may benefit from amisulpride treatment are presented.
The clinical effects of combined therapy with olanzapine and amisulpride used concurrently are promising, but further in-depth analyses of this issue are required.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Indeks Leków MP. Olanzapina.
3. Jachowicz R, Krupa A. Tabletki ulegające rozpadowi w jamie ustnej. Kierunki badań, technologie. Część I. Farm Pol. 2010; 66(6): 443-7.
4. Aptekarz Polski. Czy stosujesz już tabletki ulegające rozpadowi w jamie ustnej?.
5. Jayasree A, Shanmuganathan P, Ramamurthy P et al. Types of Medication Non-adherence & Approaches to Enhance Medication Adherence in Mental Health Disorders: A Narrative Review. Indian J Psychol Med. 2024; 0(0): http://doi.org/10.1177/02537176241233745.
6. San L, Casillas M, Ciudad A et al. Olanzapine orally disintegrating tablet: a review of efficacy and compliance. CNS Neurosci Ther. 2008; 14(3): 203-14. http://doi.org/10.1111/j.1755-5949.2008.00053.x.
7. Abbas AI, Hedlund PB, Huang M et al. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology. 2009; 205(1): 119-28. http://doi.org/10.1007/s00213-009-1521-8.
8. Indeks Leków MP.
9. Czajka-Oraniec I. Odpowiedzi na pytania do wykładu „Hiperprolaktynemia w praktyce psychiatrycznej”.
10. Schmidt-Kraepelin C, Feyerabend S, Engelke C et al. A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design. Eur Arch Psychiatry Clin Neurosci. 2020; 270(1): 83-94. http://doi.org/10.1007/s00406-019-01063-4.